EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Are There Prevalent Sex Differences in Psychostimulant Use Disorder? A Focus on the Potential Therapeutic Efficacy of Atypical Dopamine Uptake Inhibitors

Melinda Hersey iD, Mattingly K Bartole, Claire S Jones, Amy Hauck Newman, Gianluigi Tanda iD

Molecules · 07.07.2023 · 28 (13) · 5270

DOI: 10.3390/molecules28135270 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 07.07.2023. Verfasst von Melinda Hersey und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medication Development Program, NIDA IRP, Baltimore, MD 21224, USA. Hauptthemen laut MEDLINE: Central Nervous System Stimulants, Cocaine. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Intramural NIH HHS, NIDA NIH HHS, Medication Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psychostimulant use disorders (PSUD) affect a growing number of men and women and exert sizable public health and economic burdens on our global society. Notably, there are some sex differences in the onset of dependence, relapse rates, and treatment success with PSUD observed in preclinical and clinical studies. The subtle sex differences observed in the behavioral aspects of PSUD may be associated with differences in the neurochemistry of the dopaminergic system between sexes. Preclinically, psychostimulants have been shown to increase synaptic dopamine (DA) levels and may downregulate the dopamine transporter (DAT). This effect is greatest in females during the high estradiol phase of the estrous cycle. Interestingly, women have been shown to be more likely to begin drug use at younger ages and report higher levels of desire to use cocaine than males. Even though there is currently no FDA-approved medication, modafinil, a DAT inhibitor approved for use in the treatment of narcolepsy and sleep disorders, has shown promise in the treatment of PSUD among specific populations of affected individuals. In this review, we highlight the therapeutic potential of modafinil and other atypical DAT inhibitors focusing on the lack of sex differences in the actions of these agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous System StimulantsCocaineFemaleHumansMaleDopamine Uptake InhibitorsModafinilSex CharacteristicsBenzhydryl CompoundsDopamine

Stichwörter der Autor:innen

DATcocainedopaminemodafinil

Substanzen

Dopamine Uptake InhibitorsModafinilBenzhydryl CompoundsCentral Nervous System StimulantsCocaineDopamine

Autor:innen und Institutionen

  • Medication Development Program, NIDA IRP, Baltimore, MD 21224, USA.

ORCID-Profile: Melinda Hersey, Gianluigi Tanda

Förderung

  • Intramural NIH HHS
  • NIDA NIH HHS
  • Medication Development Program
  • National Institute on Drug Abuse, Intramural Research Program

Zitieren

APA

Hersey, M., Bartole, M. K., Jones, C. S., Newman, A. H., & Tanda, G. (2023). Are There Prevalent Sex Differences in Psychostimulant Use Disorder? A Focus on the Potential Therapeutic Efficacy of Atypical Dopamine Uptake Inhibitors. Molecules, 28(13), 5270. https://doi.org/10.3390/molecules28135270

Vancouver

Hersey M, Bartole MK, Jones CS, Newman AH, Tanda G. Are There Prevalent Sex Differences in Psychostimulant Use Disorder? A Focus on the Potential Therapeutic Efficacy of Atypical Dopamine Uptake Inhibitors. Molecules. 2023;28(13):5270. doi:10.3390/molecules28135270

BibTeX
@article{Hersey2023,
  author = {Hersey, Melinda and Bartole, Mattingly K and Jones, Claire S and Newman, Amy Hauck and Tanda, Gianluigi},
  title = {Are There Prevalent Sex Differences in Psychostimulant Use Disorder? A Focus on the Potential Therapeutic Efficacy of Atypical Dopamine Uptake Inhibitors},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {13},
  pages = {5270},
  doi = {10.3390/molecules28135270}
}
Kostenlos starten →